Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaxis had completed the first phase I clinical trial in healthy volunteers with its new drug candidate, PXS25. The trial was designed to determine the tolerance and pharmacokinetic profile of PXS25, following intravenous administration.
Subscribe to our email newsletter
The trial investigated five ascending doses of PXS25 in 40 subjects. At all doses, PXS25 was found to be safe and well tolerated with a pharmacokinetic profile consistent with a drug, that could be delivered once per day.
Alan Robertson, chief executive officer of Pharmaxis, said: “We have seen encouraging results from PXS25 in pre clinical testing that suggests it will be active in a range of fibrotic diseases. I am therefore delighted that, based on the results from this Phase I study, PXS25 fulfils many of the other criteria we look for in a drug. I’d like to thank those involved in this study and we look forward to developing PXS25 further.”
Additional phase I trials will be completed before PXS25 is evaluated in patients with lung disease. PXS25 is being developed as a potential new treatment for pulmonary fibrosis.